Literature DB >> 30862160

Monitoring the Immunoproteasome in Live Cells Using an Activity-Based Peptide-Peptoid Hybrid Probe.

Breanna L Zerfas1, Darci J Trader1.   

Abstract

Activity-based probes have greatly improved our understanding of the intrinsic roles and expression levels of various proteins within cells. To be useful in live cells, probes must be cell permeable and provide a read-out that can be measured without disrupting the cells or the activity of the target. Unfortunately, probes for the various forms of the proteasome that can be utilized in intact cells are limited; commercially available probes are most effectively used with purified protein or cell lysate. The proteasome, both the 26S and various isoforms of the 20S CP, is an important target with reported roles in cancer, autoimmune disorders, and neurodegenerative diseases. Here, we present the development of a selective probe for the immunoproteasome, a specialized isoform of the 20S proteasome, that becomes expressed in cells that encounter an inflammatory signal. Using a one-bead, one-compound library of small peptides, we discovered a trimer sequence efficiently cleaved by the immunoproteasome with significant selectivity over the standard proteasome. Upon conjugating this sequence to rhodamine 110 and a peptoid, we generated a probe with a considerable improvement in sensitivity compared to that of current aminomethylcoumarin-based proteasome probes. Importantly, our probe was capable of labeling immunoproteasome-expressing cells while maintaining its selectivity over other cellular proteases in live cell cultures. We anticipate this probe to find wide utility for those that wish to study the immunoproteasome's activity in a variety of cell lines and to be used as a reporter to discover small molecules that can perturb the activity of this proteasome isoform.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30862160      PMCID: PMC7389183          DOI: 10.1021/jacs.8b12873

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  47 in total

1.  A new fluorogenic peptide determines proteasome activity in single cells.

Authors:  Silvana A M Urru; Pietro Veglianese; Ada De Luigi; Elena Fumagalli; Eugenio Erba; Rodolfo Gonella Diaza; Andrea Carrà; Enrico Davoli; Tiziana Borsello; Gianluigi Forloni; Niccolò Pengo; Enrico Monzani; Paolo Cascio; Simone Cenci; Roberto Sitia; Mario Salmona
Journal:  J Med Chem       Date:  2010-10-28       Impact factor: 7.446

Review 2.  The immunoproteasome as a target in hematologic malignancies.

Authors:  Deborah J Kuhn; Robert Z Orlowski
Journal:  Semin Hematol       Date:  2012-07       Impact factor: 3.851

Review 3.  Proteasome subtypes and the processing of tumor antigens: increasing antigenic diversity.

Authors:  Nathalie Vigneron; Benoît J Van den Eynde
Journal:  Curr Opin Immunol       Date:  2011-12-27       Impact factor: 7.486

4.  Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody.

Authors:  A Porgador; J W Yewdell; Y Deng; J R Bennink; R N Germain
Journal:  Immunity       Date:  1997-06       Impact factor: 31.745

5.  Solid-phase synthesis of Rhodamine-110 fluorogenic substrates and their application in forensic analysis.

Authors:  J Gooch; V Abbate; B Daniel; N Frascione
Journal:  Analyst       Date:  2016-03-30       Impact factor: 4.616

6.  An atomic structure of the human 26S proteasome.

Authors:  Xiuliang Huang; Bai Luan; Jianping Wu; Yigong Shi
Journal:  Nat Struct Mol Biol       Date:  2016-07-18       Impact factor: 15.369

7.  Integrated, Continuous Emulsion Creamer.

Authors:  Wesley G Cochrane; Amber L Hackler; Valerie J Cavett; Alexander K Price; Brian M Paegel
Journal:  Anal Chem       Date:  2017-11-28       Impact factor: 6.986

8.  A precipitating role for truncated alpha-synuclein and the proteasome in alpha-synuclein aggregation: implications for pathogenesis of Parkinson disease.

Authors:  Chang-Wei Liu; Benoit I Giasson; Karen A Lewis; Virginia M Lee; George N Demartino; Philip J Thomas
Journal:  J Biol Chem       Date:  2005-04-19       Impact factor: 5.157

9.  Interferon gamma stimulation modulates the proteolytic activity and cleavage site preference of 20S mouse proteasomes.

Authors:  B Boes; H Hengel; T Ruppert; G Multhaup; U H Koszinowski; P M Kloetzel
Journal:  J Exp Med       Date:  1994-03-01       Impact factor: 14.307

Review 10.  The interrelationship of proteasome impairment and oligomeric intermediates in neurodegeneration.

Authors:  Jennifer M Deger; Julia E Gerson; Rakez Kayed
Journal:  Aging Cell       Date:  2015-06-05       Impact factor: 9.304

View more
  6 in total

1.  Multiplexed Enzyme Activity-Based Probe Display via Hybridization.

Authors:  Valerie Cavett; Brian M Paegel
Journal:  ACS Comb Sci       Date:  2020-09-02       Impact factor: 3.784

Review 2.  Assessing the range of enzymatic and oxidative tunability for biosensor design.

Authors:  Hattie C Schunk; Derek S Hernandez; Mariah J Austin; Kabir S Dhada; Adrianne M Rosales; Laura J Suggs
Journal:  J Mater Chem B       Date:  2020-04-29       Impact factor: 6.331

3.  Synthesis and Application of an Activity-Based Peptide-Peptoid Hybrid Probe for the Immunoproteasome.

Authors:  Breanna L Zerfas; Darci J Trader
Journal:  Curr Protoc Chem Biol       Date:  2019-12

4.  Fluorescent Probes with Unnatural Amino Acids to Monitor Proteasome Activity in Real-Time.

Authors:  Breanna L Zerfas; Rachel A Coleman; Andres F Salazar-Chaparro; Nathaniel J Macatangay; Darci J Trader
Journal:  ACS Chem Biol       Date:  2020-08-26       Impact factor: 5.100

Review 5.  Methods for the discovery of small molecules to monitor and perturb the activity of the human proteasome.

Authors:  Marianne E Maresh; Andres F Salazar-Chaparro; Darci J Trader
Journal:  Future Med Chem       Date:  2020-12-04       Impact factor: 3.808

Review 6.  Immunoproteasome in IgA Nephropathy: State-of-Art and Future Perspectives.

Authors:  Ting Gan; Yang Li; Xu-Jie Zhou; Hong Zhang
Journal:  Int J Biol Sci       Date:  2020-07-19       Impact factor: 6.580

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.